Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program
Endoscopy · 2024-05 · 56 (05) · 364-372
DOI: 10.1055/a-2230-5563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, online erschienen am 06.02.2024. Verfasst von Pieter H A Wisse und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonoscopy, Early Detection of Cancer, Occult Blood. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Post-colonoscopy colorectal cancers (PCCRCs) decrease the effect of colorectal cancer (CRC) screening programs. To enable PCCRC incidence reduction in the long-term, we classified PCCRCs diagnosed after colonoscopies performed in a fecal immunochemical test (FIT)-based screening program.
Methods
PCCRCs diagnosed after colonoscopies performed between 2014–2016 for a positive FIT in the Dutch CRC screening program were included. PCCRCs were categorized according to the World Endoscopy Organization consensus statement into (a) interval PCCRC (diagnosed before the recommended surveillance); (b) non-interval type A (diagnosed at the recommended surveillance interval); (c) non-interval type B (diagnosed after the recommended surveillance interval); or (d) non-interval type C (diagnosed after the intended recommended surveillance interval, with surveillance not implemented owing to co-morbidity). The most probable etiology was determined by root-cause analysis. Tumor stage distributions were compared between categories.
Results
116362 colonoscopies were performed after a positive FIT with 9978 screen-detected CRCs. During follow-up, 432 PCCRCs were diagnosed. The 3-year PCCRC rate was 2.7%. PCCRCs were categorized as interval (53.5%), non-interval type A (14.6%), non-interval type B (30.6%), and non-interval type C (1.4%). The most common etiology for interval PCCRCs was possible missed lesion with adequate examination (73.6%); they were more often diagnosed at an advanced stage (stage III/IV; 53.2%) compared with non-interval type A (15.9%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands.
- Gastroenterology and Hepatology, Bevolkingsonderzoek Nederland, Rotterdam, Netherlands.
- Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
- Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam, Netherlands.
ORCID-Profile: Evelien Dekker, Manon C W Spaander
Zitieren
APA
Wisse, P. H. A., de Boer, S. Y., Oudkerk Pool, M., Terhaar Sive Droste, J. S., Verveer, C., Meijer, G. A., Dekker, E., & Spaander, M. C. W. (2024). Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program. Endoscopy, 56(05), 364-372. https://doi.org/10.1055/a-2230-5563
Vancouver
Wisse PHA, de Boer SY, Oudkerk Pool M, Terhaar Sive Droste JS, Verveer C, Meijer GA, et al. Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program. Endoscopy. 2024;56(05):364-372. doi:10.1055/a-2230-5563
BibTeX
@article{Wisse2024,
author = {Wisse, Pieter H A and de Boer, Sybrand Y and Oudkerk Pool, Marco and Terhaar Sive Droste, Jochim S and Verveer, Claudia and Meijer, Gerrit A and Dekker, Evelien and Spaander, Manon C W},
title = {Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {05},
pages = {364--372},
doi = {10.1055/a-2230-5563}
}
EUVIMED